Business
Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health
Glycerol monolaurate has the potential to deliver broad antimicrobial activity to treat a variety of bacterial, fungal, and viral vaginal infections SAN
About this update from Dare Bioscience, Inc.
[{"type":"text","content":"Glycerol monolaurate has the potential to deliver broad antimicrobial activity to treat a variety of bacterial, fungal, and viral vaginal infections\nSAN DIEGO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it has entered into a license agreement with Hennepin Life Sciences LLC under which Daré acquired the exclusive global rights to develop and commercialize treatments delivering the novel antimicrobial glycerol monolaurate (GML) intravaginally for a variety of vaginal health conditions including bacterial, fungal, and viral infections. GML is a naturally occurring fatty acid monoester that has shown broad antimicrobial activity, killing bacteria, fungi and viruses and importantly, represents a new class of antimicrobial agents. Additionally, due to its mechanism of action, GML has shown low potential for the development of antibiotic resistance. In vitro testing has shown GML to be effective at inhibiting growth of the major strains of Candida causing vulvovaginal candidiasis (VVC), as well as Gardnerella vaginalis, the primary bacteria associated with bacterial vaginosis. Furthermore, a randomized, double-blind pilot study investigating the effects of GML on vaginal microflora in colonized or infected women showed reductions in Candida and Gardnerella vaginalis while not altering the healthy Lactoacillus bacterium or vaginal pH.1 “Vaginal health conditions, particularly infections such as bacterial vaginosis and VVC, which is second only to bacterial vaginosis as the reason women seek gynecological care2, remain prevalent and serious problems that can negatively impact a woman’s quality of life and create economic burden for women, employers, and the broader healthcare system. Women impacted by these conditions may have multiple episodes in a year, and treatments for one condition may increase the likelihood of developing another condition2. We believe that an antimicrobial providing a broad spectrum of activity against bacteria and fungi, but with a low potential for developing resistance, represents a unique multi-target development candidate for our portfolio. GML could both delay recurrence following an effective primary treatment of an episode, as well as mitigate common side effects of the primary treatment,” said Sabrina Martucci Johns...